Last reviewed · How we verify
Clindamycin 1 % Topical Lotion
At a glance
| Generic name | Clindamycin 1 % Topical Lotion |
|---|---|
| Sponsor | Erasmus Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (PHASE2)
- Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields (PHASE2)
- Efficacy of Laser Hair Removal Therapy in HS (NA)
- Intradermal LPS and Antibiotics (NA)
- Bioequivalence Study of Clindamycin Phosphate Topical Lotion, 1% in Subjects With Acne Vulgaris (PHASE3)
- Anti-inflammatory Effects of Topical Erythromycin and Clindamycin in Acne Patients (PHASE4)
- Microwave Ablation in Mild Axillary Hidradenitis Suppurativa (NA)
- Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clindamycin 1 % Topical Lotion CI brief — competitive landscape report
- Clindamycin 1 % Topical Lotion updates RSS · CI watch RSS
- Erasmus Medical Center portfolio CI